MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

Salinomycin sodium salt

產(chǎn)品活性：Salinomycin sodium salt (Salinomycin sodium)，一種鉀離子載體抗生素，是 Wnt/β-catenin 信號傳導的有效抑制劑。Salinomycin sodium salt (Salinomycin sodium) 作用于 Wnt/Fzd/LRP 復(fù)合物，阻斷 Wnt 誘導的 LRP6 磷酸化，導致 LRP6 蛋白降解。Salinomycin sodium salt (Salinomycin sodium) 選擇性抑制人腫瘤干細胞。

研究領(lǐng)域：Stem Cell/Wnt  |  Anti-infection  |  Autophagy  |  Apoptosis

作用靶點：Wnt  |  β-catenin  |  Bacterial  |  Autophagy  |  Apoptosis  |  Antibiotic  |  Parasite

In Vitro: Salinomycin (0.1-8 µM) inhibits the growth of HUVECs in a dose-dependent manner, accounting for 32.1 and 59.2% inhibition at 4 and 8 µM, respectively. HUVECs exposed to 2, 4 and 8 µM of Salinomycin for 48 h show a dose-dependent reduction in cell number and a change in cell morphology. Salinomycin (4 µM) treatment effectively inhibits HUVEC migration and invasion, and significantly disrupt the capillary-like tube formation of HUVECs. Salinomycin significantly suppresses the expression levels of phosphorylated (p)-FAK in a time- and dose-dependent manner in HUVECs. Salinomycin inhibits HUVEC angiogenesis by disturbing the VEGF-VEGFR2-AKT signaling axis. Combination of RSVL and Salinomycin synergistically inhibits the proliferation of TNBC (MDA-MB-231) cells. RSVL and Salinomycin effectively reduce wound healing, colony and tumorosphere forming capability in TNBC cells. Synergistic combination of RSVL and Salinomycin induces apoptosis in both culture conditions by significant upregulation of Bax with decreased Bcl-2 expression as comparison to untreated and alone drug treatments. Salinomycin (0, 2, 4, 8 and 16 μM) significantly inhibits the proliferation of A2780 and SK-OV-3 cell lines in a dose- and time-dependent manner, (IC_{50 24h}: 13.8 μM, IC_{50 48h}: 6.888 μM and IC_{50 72h}: 4.382 μM for A2780 cell lines), (IC_{50 24h}: 12.7 μM, IC_{50 48h}: 9.869 μM and IC_{50 72h}: 5.022 μM for SK-OV-3 cell lines). Salinomycin blocks the Wnt/β-catenin pathway in EOC cells. Salinomycin (2 μM) reduces cancer cell proliferation, inhibits STAT3 phosphorylation and P38 and β-catenin expressions, and suppresses epithelial-mesenchymal transition in colorectal cancer cells. Salinomycin (1-5 μM) inhibits cancer cell proliferation and STAT3 signaling in colorectal cancer cells. Furthermore, Salinomycin activates Akt (Ser 473) and down-regulates Hsp27 (Ser 82) phosphorylation in HT-29 and SW480. Salinomycin down-regulates hTERT and reduces telomerase activity when combined with telomerase inhibitor.

In Vivo: Salinomycin (5 and 10 mg/kg) significantly supresses the average tumor volume and tumor weight. Salinomycin hinders the U251 human glioma cell growth in vivo via inhibition of angiogenesis with involvement of AKT and FAK dephosphorylation. Salinomycin (0.5 mg/kg b.wt.) enhances the mean survival time of the tumor bearing Swiss albino mice.

相關(guān)產(chǎn)品：Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Stem Cell Signaling Compound Library  |  Wnt/Hedgehog/Notch Compound Library  |  Anti-Cancer Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Differentiation Inducing Compound Library  |  Antibacterial Compound Library  |  Cytoskeleton Compound Library  |  Antibiotics Library  |  Neuroprotective Compound Library  |  Anti-Breast Cancer Compound Library  |  Antiparasitic Compound library  |  Transcription Factor-Targeted Library  |  Anti-Liver Cancer Compound Library   |  Rare Diseases Drug Library  |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Antihypertensive Compound Library  |  Membrane Protein-targeted Compound Library  |  SY-5609  |  Antifungal agent 26  |  BRD4 Inhibitor-18  |  8α-Tigloyloxyhirsutinolide 13-O-acetate  |  (1R,2S,7R)-Sitafloxacin-d₄ (hydrochloride)  |  Quinidine-d₃  |  Nebacumab  |  Angulatin G  |  Acridine Orange base  |  N-Desethyl amodiaquine-d₅  |  Doxorubicin-¹³C,d₃ (TFA)  |  Gepotidacin  |  Amycolatopsin A  |  Palitantin  |  Antibiotic A-33853  |  Estradiol hemihydrate  |  AAPK-25  |  Sulbactam-d₂ (sodium)  |  Dutasteride-¹³C₆  |  Oleic acid-¹³C  |  Antimicrobial agent-5  |  Proguanil-d₆  |  NBTIs-IN-4  |  Proanthocyanidin  |  Azlocillin sodium salt  |  Abacavir sulfate  |  Antitubercular agent-13  |  Meloxicam-d₃-1  |  Thailanstatin D

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫，我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤最新的制藥及生命科學研究進展，為您提供全球新的活性化合物；
•   與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。